Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
KADMON HLDNGS RG (NY: KDMN)
3.600 USD  -0.060 (-1.64%)
Official Closing Price  /  Updated: 8:04 PM EDT, May 25, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 364,902
Open 3.650
Bid (Size) 3.210 (1000)
Ask (Size) 4.390 (500)
Prev. Close 3.660
Today's Range 3.560 - 3.680
52wk Range 2.050 - 5.860
Shares Outstanding 78,794,746
Dividend Yield N/A
Performance
YTD
-1.10%
-1.10%
1 Month
-13.67%
-13.67%
3 Month
-3.74%
-3.74%
6 Month
-1.37%
-1.37%
1 Year
+46.94%
+46.94%
Top News
More News
Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett & Platt, and Esterline Technologies — Research Highlights Growth, Revenue, and Consoli
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of USA Compression Partners,... Read More
from GlobeNewswire News Releases
Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that additional data from its ongoing Phase 2 clinical trial of KD025 in chronic graft-versus-host disease (cGVHD) will be highlighted in an oral... Read More
from Business Wire News Releases
More News
Read More
Modestly higher close on upbeat earnings
category Market News
from MarketMinute.com Market Updates
Kadmon Provides Business Update and Reports First Quarter 2018 Financial Results
from Business Wire News Releases
Kadmon Holdings reports positive study results
from MarketMinute.com Stock News
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
from Business Wire News Releases
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
from Business Wire News Releases
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
from Business Wire News Releases
Analysts See 13% Gains Ahead For SPTM
category ETFs
from ETF Channel
BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease
category companyNews
from Reuters: Company News
BRIEF-Kadmon Qtrly ??loss Per Share $0.24
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account